Hims & Hers' shift to branded obesity drugs drives wider quarterly loss | Reuters

Hims & Hers posts wider loss as shift to branded weight-loss drugs drives up costs

Hims & Hers Health reported a wider-than-expected second-quarter loss as the telehealth company's shift to branded weight-loss drugs drove up costs, sending shares down 6% in extended trading. The company plans to enter the peptides market before year-end.